Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients - Wikidata - wikimedia - TriplyDB

Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients

Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients

http://www.wikidata.org/entity/Q33383622

about

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review Risk of thrombosis and thromboembolic prophylaxis in obesity surgery: data analysis from the German Bariatric Surgery Registry.Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.Evaluation of an enoxaparin dosing calculator using burn size and weight.Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Prevention of venous thromboembolism in obesity.Reasons, procedures, and outcomes in ventriculoatrial shunts: A single-center experience Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia Anticoagulating obese patients in the modern era.Perioperative management of the severely obese patient: a selective pathophysiological review.Pharmacologic prevention of venous thromboembolism in obese patients.A review of venous thromboembolism prophylaxis for hospitalized medical patients.Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients.Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety.Is LMWH Sufficient for Anticoagulant Prophylaxis in Bariatric Surgery? Prospective Study.Optimizing care for the obese patient in interventional radiology Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients.Venous Thromboembolism in Critically Ill Medical Patients Receiving Chemoprophylaxis: A Focus on Obesity and Other Risk Factors.Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.A population-level analysis of abdominal wall reconstruction by component separation in the morbidly obese patient: can it be performed safely?Clinical markers of the hypercoagulable state by rotational thrombelastometry in obese patients submitted to bariatric surgery.Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study.The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study.Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients.The defined daily doses of low molecular weight heparins do not reflect current clinical practice.Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.Identifying the Bariatric Patient at Risk for Pulmonary Embolism: Prospective Clinical Trial Using Duplex Sonography and Blood Screening.Role of thrombolestagrophy in monitoring perioperative coagulation status and effect of thromboprophylaxis in bariatric surgery.Cesarean delivery in the obese parturient: anesthetic considerations.Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.Adjusted-Dose Enoxaparin for VTE Prevention in the Morbidly Obese.Low-Molecular-Weight Heparin Prophylaxis Dosing: Is Weight an Issue?

P2860

Q26770822-AE598E3D-EF03-40D5-87AE-D9E7E81C2801 Q26992262-CF1612A7-625D-4452-AE98-FBEB621C483A Q31084567-3CB70712-0B6D-4742-A63E-B53CFDA5AF46 Q33401095-170607E4-7456-4C54-87BC-164AED48F028 Q33410373-88DA54FB-121E-4F80-BE65-B95D79F91406 Q34612869-5C71AFB4-1165-4BAE-BE09-ABB48B012705 Q35154142-4D886B27-86F3-46B1-8D29-9A2A26EE1CB7 Q35633708-7B12992F-FA71-499B-B92B-C5F63DC07035 Q36661093-7F5ADD2D-946E-4C5F-9266-B8A0A058269C Q37152911-C92C51BA-81C6-47A1-B127-9E9F19F26C01 Q37919151-2B4A47E1-6C14-477B-8ACD-24E7013EC1C5 Q38029544-42737FFA-ABC9-4A11-A38C-D4FC6042D72C Q38062477-DE3D8082-28F0-423A-BE51-A26B9D1E34DE Q38129188-F6D8A626-52F8-4E68-A99E-E28E0941240E Q38168477-C9D7C711-1668-47D8-8938-B6FC3D5BFB98 Q38485825-B4B8CB07-DB40-48B0-A13E-8B78CF590028 Q38633482-C6944EEE-52F4-4AB3-BF52-EC3B5FE9A947 Q38888249-56C4CF89-4AED-4C53-B343-6930EE7A7F7C Q39084404-FC1828C2-36BC-4315-ACC3-B97AE8ECA9A4 Q41231279-EBEEB7FF-6FE5-4AAD-BEBF-9CA25A7D1516 Q41394993-810FA111-E8EB-4835-A591-0D8B25D45808 Q43426032-6B2DA8CA-6F05-45E1-ABAC-0128FD03B295 Q43513155-F3F98029-E9B5-40E1-917E-F78EBAE621BC Q44926539-CF7E1CF9-2379-4989-8B46-F8A919750A11 Q45727029-D456929E-A349-4D7A-AB0E-A55BF1120347 Q46105580-787A5EA5-8778-4B53-8412-FF39A14E3C42 Q46618514-E5B287B7-3FAC-48BB-A67A-177F3095C1EB Q46831995-FBD3E4F7-CC97-4A79-8C09-5BFFEB484E5B Q47328313-024FB878-633D-4C82-B0F9-814EA763C589 Q47349893-E1D6A844-6CFF-4F3E-A9F9-1106130C9156 Q47431339-94B5463B-4166-4D10-8583-196AB03B8BE8 Q47985617-2B230004-00C7-4FAC-9D2D-D30F25E70527 Q48261051-A334E1A8-394F-4616-ACBA-F04C9C6AC65A Q48278730-AF81ADE5-EC61-4F2B-9472-D8DAEA6C284C Q50999671-D6C585D3-E1B1-4A8F-92F3-01E3F3552FC3 Q53101380-B23DED4A-B8FA-4629-AC05-C0800BF75EBE Q55235456-B89C1900-B23F-48ED-8785-1852EEBD65A7 Q55261242-716ABBFE-F269-4635-A9D6-FF60765BE683

P2860

Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients

http://www.wikidata.org/entity/Q33383622

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Weight-based dosing of enoxapa ...... obese, medically-Ill patients

@ast

Weight-based dosing of enoxapa ...... obese, medically-Ill patients

@en

type

label

Weight-based dosing of enoxapa ...... obese, medically-Ill patients

@ast

Weight-based dosing of enoxapa ...... obese, medically-Ill patients

@en

prefLabel

Weight-based dosing of enoxapa ...... obese, medically-Ill patients

@ast

Weight-based dosing of enoxapa ...... obese, medically-Ill patients

@en

P1433

Q33383622-2FA0BD8A-7A35-402F-BA4F-C81992EACBE2

P1476

Q33383622-150D434E-EB8B-40B5-91E1-87DB1BF1F4D3

P2093

Q33383622-126D289A-E5DF-4335-8473-1F6A3D22A98E

Q33383622-3D98E660-38B6-454A-8879-2C043934ECD1

Q33383622-5A711C33-C42A-42FF-A714-B31E4DF99B70

Q33383622-78206C9F-7FBA-487E-8FAB-59EB6680D0A3

Q33383622-E1EB995D-571F-4EE8-AC4E-20F81343C154

P2860

Q33383622-1993FD0A-F870-424F-8263-F256974A7B48

Q33383622-25D8C2BA-CE70-469F-B3E7-8607DF16EF86

Q33383622-2AA76D66-4E95-46A8-9483-3E339007D97F

Q33383622-3830441A-55D7-466C-B351-FE33B1899016

Q33383622-3F0B6D98-979B-494D-9A83-3DB541189E6A

Q33383622-3F898089-598D-4E82-84BE-F434365642A0

Q33383622-40BDAB26-E08B-471D-9D31-34304CB15A7A

Q33383622-4CFDF086-52F2-4F67-A1C2-3981BF58BB27

Q33383622-526E4745-27A4-4F6D-97EA-C2B7E3C79303

Q33383622-58EFC75B-AF6F-4F91-845B-62007E50F335

P304

Q33383622-00F67068-B9E3-40ED-BB75-32B503853BF8

P31

Q33383622-9D341774-5B10-4F58-BB58-B1DE2DFC4F0C

P356

Q33383622-16A2021E-54E7-4583-BF4D-AD2ADDC55B2B

P433

Q33383622-0C87D2C5-6F85-4B2E-87EA-15F9C2C014F8

P478

Q33383622-DE9799AE-A045-4F6B-97CB-744BAB28B51D

P577

Q33383622-3939D07C-8C40-4FF7-B69A-E9FCDC9225F6

P5875

Q33383622-4AA41798-3602-4EB0-986F-438C32B16858

P698

Q33383622-EB6BFA31-B223-4FFD-8522-209D29682EFB

P921

Q33383622-3FA0039A-9C6F-4C00-B406-D6C8754E9D69

P932

Q33383622-724FD0ED-77D5-4250-9D81-84D94E6BD409

P356

J.THROMRES.2009.02.003

P1433

Thrombosis Research

P1476

Weight-based dosing of enoxapa ...... obese, medically-Ill patients

@en

P2093

George M Rodgers

http://www.w3.org/2001/XMLSchema#string

Leslie Draper

http://www.w3.org/2001/XMLSchema#string

Matthew T Rondina

http://www.w3.org/2001/XMLSchema#string

Michelle Wheeler

http://www.w3.org/2001/XMLSchema#string

Robert C Pendleton

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Dosing and monitoring of low-molecular-weight heparins in special populations.

Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients.

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Effects of obesity on pharmacokinetics implications for drug therapy.

Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.

Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery.

Low molecular weight heparin and bleeding in patients with chronic renal failure.

Epidemiology of obesity in the Western Hemisphere.

Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.

P304

220-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.THROMRES.2009.02.003

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24187964

http://www.w3.org/2001/XMLSchema#string

P698

19272635

http://www.w3.org/2001/XMLSchema#string

P921

P932

3245965

http://www.w3.org/2001/XMLSchema#string